News & Events

News

All categories

Earnings

Press Release

All years

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors

February 3, 2021

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 15, 2021

Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares

January 13, 2021

Affimed Announces Proposed Public Offering of Common Shares

January 12, 2021

Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 11, 2021

Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank

January 11, 2021

Affimed Announces Pipeline and Business Update

January 7, 2021

Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma with Cutaneous Presentation

December 7, 2020

Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood

November 19, 2020

Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress

November 10, 2020

Events

All

Scientific

Investors

23Mar

Innate Killer Summit

March 23 - 25, 2021 (virtual)

Webcasts
More events